Scientists make critical insights into T-cell development

August 11, 2017, Monash University
Scientists make critical insights into T-cell development
Credit: Monash University

Mutations in the gene encoding the enzyme protein tyrosine phosphatase N2 (PTPN2) have been associated with the development of autoimmune disease including Type 1 diabetes, Crohn's Disease and rheumatoid arthritis.

In important fundamental research, Monash University researchers have identified a crucial part of the enzyme's role in early T-cell , and have shown that decreased levels of this enzyme can lead to the type of T-cells that can contribute to the development of autoimmune disease.

Autoimmune diseases represent a broad spectrum of diseases, which arise when immune responses are directed against, and damage, the body's own tissues. Collectively their incidence exceeds that of cancer and and they are a leading cause of death and disability, in particular in the Western world.

The Monash Biomedicine Discovery Institute researchers had already shown in studies over the years that decreased levels of PTPN2 result in T-cells attacking the body's own cells and tissues.

In a paper published in the Journal of Experimental Medicine, they drilled deeper, exploring roles for the enzyme in early T-cell development and the development of particular T-cell subsets (αβ and γδ) implicated in the development of different autoimmune and inflammatory diseases.

By removing the gene coding for PTPN2 in laboratory trials, the scientists found that the developmental process for T-cells was skewed towards the generation of γδ T cells with pro-inflammatory properties that are known to contribute to the development of different diseases including Irritable Bowel Disease, Crohn's Disease and rheumatoid arthritis.

"This is an important advance in our understanding of critical checkpoints in T-cell development," lead researcher Professor Tony Tiganis said.

"It helps decide whether the progenitors go on to become T-cells or something else; if they become one type of T-cell or another type," he said.

As part of the study, the researchers looked at the pathways that PTPN2 regulates.

"There are drugs that target some of these pathways – potentially we might be able to use existing drugs to target these pathways in the context of autoimmune and to help a subset of patients with a deficiency in this gene, although that is a long way off," Professor Tiganis said.

First author Dr Florian Wiede said, "Understanding the mechanisms that govern early T-cell development and how these are altered in human disease may ultimately afford opportunities for novel treatments. This is very exciting."

Explore further: New gene mutations found in white blood cells in patients with rheumatoid arthritis

More information: Florian Wiede et al. PTPN2 regulates T cell lineage commitment and αβ versus γδ specification, The Journal of Experimental Medicine (2017). DOI: 10.1084/jem.20161903

Related Stories

New gene mutations found in white blood cells in patients with rheumatoid arthritis

June 21, 2017
Gene mutations accumulating in cells are typical of the development of cancer. Finnish researchers have found that a similar accumulation of mutations occurs also in some patients with rheumatoid arthritis.

Tpl2 enzyme may be target for treating autoimmune diseases

May 22, 2015
New research at the University of Georgia has found that the presence of Tpl2—an enzyme that regulates inflammation—controls the activation of T cells during colitis, an autoimmune disease that occurs when the inner lining ...

Immune cell death safeguards against autoimmune disease

September 6, 2012
Researchers at the Walter and Eliza Hall Institute have discovered that a pair of molecules work together to kill so-called 'self-reactive' immune cells that are programmed to attack the body's own organs. The finding is ...

Preventing too much immunity

December 27, 2016
Scientists at the Immunology Frontier Research Center (IFReC), Osaka University, Japan, report a new molecular mechanism that could explain the cause of some autoimmune diseases.

Trigger for autoimmune disease identified

May 11, 2017
Researchers at National Jewish Health have identified a trigger for autoimmune diseases such as lupus, Crohn's disease and multiple sclerosis. The findings, published in the April 2017 issue of Journal of Clinical Investigation, ...

Battle of the bulge occurs in the liver

June 20, 2014
(Medical Xpress)—An international team of scientists led by Monash University researchers has shown how free radicals contribute to type 2 diabetes, obesity and fatty liver disease.

Recommended for you

Improving vaccines for the elderly by blocking inflammation

January 22, 2018
By identifying why skin immunity declines in old age, a UCL-led research team has found that an anti-inflammatory pill could help make vaccines more effective for elderly people.

Novel genomic tools provide new insight into human immune system

January 19, 2018
When the body is under attack from pathogens, the immune system marshals a diverse collection of immune cells to work together in a tightly orchestrated process and defend the host against the intruders. For many decades, ...

First vaccine developed against grass pollen allergy

January 18, 2018
Around 400 million people worldwide suffer in some form or other from a grass pollen allergy (rhinitis), with the usual symptoms of runny nose, cough and severe breathing problems. In collaboration with the Viennese firm ...

Genomics reveals key macrophages' involvement in systemic sclerosis

January 18, 2018
A new international study has made an important discovery about the key role of macrophages, a type of immune cell, in systemic sclerosis (SSc), a chronic autoimmune disease which currently has no cure.

Researchers discover key driver of atopic dermatitis

January 17, 2018
Severe eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition that is driven by an allergic reaction. In their latest study, researchers at La Jolla Institute reveal an important player that promotes ...

Who might benefit from immunotherapy? New study suggests possible marker

January 16, 2018
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.